Pharma major Eli Lilly and Company today announced launch Humalog 200U/mL KwikPen -- used in the treatment of diabetes -- in the Indian market.
Humalog 200U/mL KwikPen is a pre-filled pen containing a concentrated formulation of Lilly's rapid-acting insulin Humalog.
"Humalog 200U/mL KwikPen... Contains concentrated 200U/mL rapid-acting insulin and delivers the same units of insulin in half the volume as 100U/mL meal-time insulin pens. It holds twice as many insulin units, hence it lasts longer and allows fewer pen changes every month," the company said in a statement.
"Patients may require dosage increase over time for better glycemic control. Humalog 200U/mL KwikPen provides physicians a new prescription option for their patients," Eli Lilly and Company (India) MD Edgard Olaizola said.
Medical Director Tarun Puri said: "Humalog 200U/mL KwikPen is bioequivalent to Humalog 100U/mL. Therefore, similar efficacy and safety as Humalog 100U/mL.
(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)